Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "UST"

5275 News Found

Ind-Swift earns EcoVadis silver medal for sustainability excellence
Sustainability | March 05, 2026

Ind-Swift earns EcoVadis silver medal for sustainability excellence

The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement


Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth
News | February 26, 2026

Sanofi Consumer Healthcare India reports robust Q4 and FY’25 growth

For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales


Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ
News | February 25, 2026

Formosa strikes exclusive deal with Arrotex to launch eye surgery drug in Australia & NZ

The innovative eyedrop targets inflammation and pain following ocular surgery


Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Clinical Trials | February 17, 2026

Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD

Duvakitug was well tolerated and safety was consistent with the induction study


IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
News | February 13, 2026

IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY


Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth
News | February 13, 2026

Supriya Lifescience delivers robust Q3 FY26 performance with 11% YoY revenue growth

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25


Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million
News | February 11, 2026

Apollo Hospitals reports robust Q3 earnings; profit after tax humps to Rs. 3,835 million

Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025


Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive
News | February 09, 2026

Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive

The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses


HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology
News | February 09, 2026

HCG reports robust Q3 & 9M FY26 growth, strengthening its lead in Indian oncology

HCG clinicians contributing to one of the largest bodies of oncology research from India


Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease
Drug Approval | February 07, 2026

Zydus receives USFDA ODD for Desidustat for the treatment of sickle cell disease

This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease